Stockreport

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosace...

Journey Medical Corporation  (DERM) 
Last journey medical corporation earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com
PDF DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoint [Read more]